Redeye provides an initial take following Senzime’s Q2 2026 report.
Hyresintäkter ökade till 208,4 (190,4) miljoner kronor under det andra kvartalet 2026, motsvarade en...
Net sales and adjusted EBITA were around 1% above market consensus (LSEG) in Q2.
Fiskars Q2 adjusted EBIT of EUR 7.7m came 40% below Modular Finance consensus expectations with 4% ...
Camurus delivered a record second quarter, with Buvidal sales surpassing SEK0.
Ahead of NoHo's Q2 2026 report, due on 4 August, we lift our estimates slightly to reflect the posit...
We raise our 2026-28 adjusted EBITA estimates by 3% following a solid Q2 report from Elanders, showi...
A stable quarter, but below the outstanding Q1 despite Q2 being seasonally stronger.
* We cut '26e-'28e adj. EBITA by 1% on temporary DK weakness * Positive development below surface, s...
Redeye comments on Vertiseit's Q2 report, showing an ARR matching our expectations alongside a solid...
Redeye take a more positive stance towards Hexatronic following the strong Q2 report, showing a stro...
* Different stories depending on segment... * ...overall better than we expected.
Ahead of Q2 we make only minor estimate changes following the recent fundraising activities.
* EBITA margin -90bp y-o-y driven by well-flagged UK logistics.
Ependion’s second quarter showed continued strong order intake and higher sales than we expected.
The report reinforced our positive view on Xvivo's underlying sales development, with heart sales cl...
Ahead of Xplora's Q2 report, we lower our 2026-28 EBITDA estimates by 2-10%, mainly due to the empor...
Ahead of Atria's Q2 report, we make only minor estimate revisions and derive a DCF- and multiples-ba...
* Sales +1%, EBITA +11% vs. ABGSCe, 3% org. growth * '26e-'28e EBITA estimates likely up 3-7% * Shar...
In July 2025, Endocrine Society delivered the most consequential catalyst for Pentixapharm's late- s...
